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features of the disease [19]. This is apparent from clinical observation 
and empirical evidence where apathy is negatively associated with 
patient’s quality of life [24]. Furthermore, caregiver burden in HD is 
driven by feelings of isolation and the sense that they are putting their 
lives on hold whilst caring for the patient [25]. If a patient socializes and 
interacts less and stops engaging in hobbies and activities due to their 
level of apathy these feelings are likely to be amplified, although this has 
never been formally assessed in the context of HD. Thus, the impact of 
apathy is clear as is the potential to improve the quality of life of both 
patients and their caregivers and to delay the need for costly residential 
care through treating it. 
Cross-sectional cohorts studies have shown that apathy maps closely 
to disease progression [7,15,22,26,27]. Given how many patients are 
affected by apathy and the impact it has on disease, it has been suggested 
that apathy should be considered a core trait of the HD15 and as such, 
should be treated as a priority in the clinical care of patients. However, 
it is currently understudied in HD and not enough is known about its 
etiology or pathophysiology to be able to treat it effectively. This is in 
part due to the poverty of validated assessment tools available for use 
in HD and the lack of methodological consistency in the literature. 
But it may also be due to the overlap between similar conditions, such 
as depression, abulia, alexthymia and other disorders of motivation 
which also occur in HD, making it difficult for clinicians to recognize 
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Introduction
Huntington’s disease is a rare autosomal-dominant neurodegenerative 
disorder caused by the expansion of a CAG triplet in the huntingtin 
gene, affecting approximately 2.71 people per 100,000 worldwide [1]. It 
is a fatal condition that typically develops between the ages of 30 and 50 
years old [2,3] and progresses over a 20 year period [4]. During this time, 
patients experience a range of problems including a movement disorder 
[5], cognitive dysfunction and neuropsychiatric symptoms [6]. The 
exact profile of these features varies between patients but the typical non 
motor features include executive dysfunction [7,8] memory problems [9] 
irritability and disinibition [10], depression [11], anxiety [12] and apathy 
[13]. For some people, these symptoms can appear before the motor 
abnormalities5 and are the strongest predictors of loss of independence 
and the need for residential care [14].
Within the psychiatric domain, apathy is thought to be one of the 
most common features of HD. Studies suggest that between 11% [13] 
and 64% [15] of premanifest and 47% to 76% [15-19] of manifest HD 
patients (Table 1) experience some degree of apathy at some point 
during their disease and that apathetic symptoms are associated with 
cognitive, motor and functional decline [20,21]. Nonetheless, not all 
patients experience apathy. Van Duijn et al. [13] reported that 52% 
of mutation carriers experienced no apathy and those who did were 
more likely to be male, with lower functional capacity scores and 
have a history of depressive episodes (and a previous suicide attempt), 
obsessive-compulsive symptoms and benzodiazepines or antipsychotics 
use. This work both confirmed and added to this group’s previous 
study [22] which found that, in comparison to non-apathetic mutation 
carriers, apathetic participants were more often older and showed worse 
global and executive cognitive function. Interestingly though, unlike 
other psychiatric features, apathy did not seem to be inheritable [23].
Importantly, apathy is considered a significant problem by patients 
and caregivers alike who both rank it as one of the three most impactful 
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Apathy is one of the most common psychiatric symptoms experienced by patients with Huntington’s disease 
(HD). It appears early, progresses with the disease course and has been shown to contribute significantly to 
caregiver burden. However, what is understood by apathy in HD is not clearly defined nor the underlying mechanisms 
responsible for it. In this review, we discuss the concept of apathy in the context of HD and propose that a consensus 
regarding its conceptualisation and subsequently its diagnostic criteria would significantly benefit the field. 
In order to undertake this work, we began by reviewing the existing literature on the definition and assessment 
of apathy in HD, its underlying neurobiological basis and its relationship to other related features such as abulia, 
anhedonia and alexithymia. 
In the context of HD, apathy could be described by a loss of or diminished motivation, emotion and goal-directed 
behaviour that is not best explained by motor or social constraints of the disease. However, there is an urgent need 
to better understand the characteristics of apathy specifically in HD, how they evolve across the disease course and 
how they relate to central dopaminergic pathways. Only by undertaking such work can we hope to better understand 
this early and disabling aspect of HD.
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it. To address these issues, we decided to review the existing literature 
concerning the current definition of apathy, the assessment tools 
used to measure it and how good they are at separating apathy from 
similar conditions. We then examined work that sought to define the 
underlying neurobiological substrates for apathy, borrowing from other 
related conditions such as Parkinson’s disease (PD) to propose avenues 
for future investigation. We conclude by suggesting further research 
directions that could help to advance the knowledge of apathy in HD 
and through this identify more effective treatments for it.
What is Apathy?
Definitions of apathy
Classically, apathy is defined as a flattening of affect, in which a patient 
exhibits an abnormal lack of feeling, interest or concern and regarded 
as a state of non-reactivity [28]. Marin, in 1990, was the first to consider 
apathy as more than a symptom but as a distinct psychiatric syndrome and 
described it as a state of primary motivational impairment not attributable to 
diminished levels of consciousness, cognitive deficits or emotional distress 
[29]. Through the use of scales such as the Apathy Evaluation Scale (AES) 
[30] most HD research conducted to date has adopted Marin’s definition 
of apathy. Yet, reducing apathy simply to an impaired motivational state 
makes it difficult to objectively assess and fails to take into consideration 
the other well reported symptoms such as lack of initiative and poverty of 
self-generated actions that seem to be core features of it. In addition, Marin’s 
conceptualization excludes apathy in the context of cognitive dysfunction 
but evidence suggests these are dissociable phenomenon, as while apathy 
can occur in the absence of cognitive dysfunction [28], it is also commonly 
reported in conditions that are also associated with cognitive dysfunction 
such as Parkinson’s disease [31], Front temporal dementia [32], Alzheimer’s 
disease [33], traumatic brain injury [34] and stroke [35]. Furthermore, 
some studies have found strong positive correlations between apathy and 
cognitive impairment [35,36], suggesting that while Marin’s exclusion 
criterion of cognitive deficits may be appropriate when looking at apathy in 
a healthy population, it is too strict for clinical studies.
Levy and Dubois took the alternative viewpoint and proposed a fully 
operational account of apathy, describing it as “a quantitative reduction 
in self-generated or purposeful behaviour” [37]. Consequently, apathy 
can be identified by a simple quantification of the number of activities 
HD patients initiate and engage in. However, this approach has several 
limitations: firstly, there are many reasons why a patient with HD 
displays a reduction in their “self-generated and purposeful behaviours”, 
not least because they find these activities harder to do due to their 
emerging movement disorder. Secondly, a quantifiable reduction in 
behaviours only happens at a relatively advanced stage of apathy. Prior 
to this the changes may be subtle and easy to miss or may be better 
reflected by the amount of additional effort a patient has to undertake 
in order to maintain their regular levels of activity. Either way, Levy 
& Dubois’s definition is poorly equipped to measure the very early 
changes that are common in the prodromal and early phases of HD. 
Finally, its broad scope makes it difficult to differentiate apathy from 
other psychopathological concepts of abnormal drive and motivation 
such as abulia or anhedonia. 
More recently, Starkstein and Leentjens [28] has built upon Marin’s 
definition by extending it to include a temporal element and formulating 
it into diagnostic criteria (Table 2). Their work was further refined by an 
international task force in 2008 to produce the consensus criteria for the 
diagnosis of apathy in Alzheimer’s disease and other neuropsychiatric 
disorders [38]. The aim of these consensus criteria was to facilitate the 
accurate identification, description and treatment of apathy in both 
clinical and research settings. It has achieved this by broadening the 
scope of behaviour that is considered supportive of a diagnosis of 
apathy whilst accepting that this behavior does not necessarily occur 
in all domains (e.g. goal-directed behavior, goal-directed cognition 
and emotion). Consequently, although Marin’s description of apathy 
has been the one most widely adopted in the literature, going forward 
we feel that there is a clear rationale for utilizing the criteria identified 
by the International Task Force as the most appropriate and useful 
definition of apathy in the context of HD. Of note, the Statistical Manual 
of Mental Disorders (DSM-V) [39] and the International Classification 
of Diseases (ICD-10) [40] do not recognize apathy as a syndrome and 
consider it as a supporting symptom for several psychiatric diseases, 
including HD, warranting no definition or criteria. But importantly, 
considering apathy as either a symptom (of, for example, depression) or 
as a syndrome does not need to be mutually exclusive [28] and indeed 
may represent a number of related but separable states [41]. 
Apathy: State vs. trait
While the definitions above conceptualize apathy as an acquired 
disorder, it can also be a trait and contextualized within the spectrum 
of individual differences. Marin, in his early work, proposed that 
apathy could not only be classified as a clinical syndrome but also as an 
adaptive trait of healthy individuals [29]. People that have a personality 
characterized by lower agreeableness, less openness to experience 
and lower extroversion may be considered inherently more apathetic. 
Indeed, apathy as a trait has been reported in healthy young adults [42] 
and community dwelling older adults [43]. To our knowledge no study 
has looked at the possibility of apathy being a trait in patients with 
HD that is exacerbated with disease onset and progression, but it may 
explain some of the individual differences in apathetic symptoms seen 
clinically and certainly warrants further exploration. 
Overlapping conditions
Study Sample Size Disease Stage Assessment Tool Used Cutf-off Prevalence
van Duijn, et al. [13] 1993 Mutation carriers from premanifest to late HD UHDRS scale score of ≥ 2 47.4%
Martinez-Horta et al. [15] 34 Premanifest individualsfar-from motor-based HD onset Short PBA-HD scale score of ≥ 2 23%
Martinez-Horta et al. [15] 25 Premanifest individualsclose-to motor-based HD onset Short PBA-HD scale score of ≥ 2 64%
Martinez-Horta et al. [15] 70 Patients with Early manifest HD Short PBA-HD scale score of ≥ 2 63%
Martinez-Horta et al. [15] 101 (Not applicable) Controls Short PBA-HD scale score of ≥ 2 2%
Simpson et al. [19] 556 HD Manifest patients Customized Survey on HD symptoms Not clear 46.3%
Naarding et al. [17] 34 HD Manifest patients AES score of ≥ 40 52%
Paulsen et al. [16] 52 HD Manifest patients NPI scale score >1 55.8%
Craufurd et al. [56] 134 HD Manifest patients PBA-HD scale score of ≥ 2 76%
Table 1: Summary of apathy prevalence rates in samples of patients with HD and controls when applicable.
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The symptoms of apathy share many features with other conditions 
that affect the motivational spectrum. Differentiating between 
depressed mood, apathy, abulia, alexithymia and anhedonia can be 
difficult because of the similarity of their clinical features [44]. There 
are many more clinical conditions that, if present, may confound the 
accurate diagnosis of apathy in HD, such as anergia, hopelessness and 
others on the negative affect and akinetic spectrum. Understanding the 
boundaries that each of these conditions shares with apathy may inform 
our knowledge of how to better define and manage them all in HD. 
Abulia: Abulia is usually defined as a lack of will or motivation [45]. 
From a conceptual standpoint, abulia and apathy are on a continuum 
of motivational and emotional deficit and it has been proposed that 
abulia represents the more severe part of the continuum [28], which 
at its most extreme leads to akinetic mutism [46]. However, this is a 
conceptual framework that is not strongly based on empirical research 
but rather on the clinical understanding that apathy tends to produce 
abulia in more severe neurological conditions [29]. For example, in a 
review of 240 cases from the literature, Bhatia and Marsden reported 
that abulia was recorded in approximately 28% of patients with a focal 
lesion to the caudate [47]. Interestingly, a Delphi survey involving 35 
neurologists and 30 psychiatrists showed that there was no consensus 
about whether abulia and apathy represent distinct phenomena and if 
and how, they differed in terms of severity [48], highlighting the need 
for more precise differential definitions and diagnostic criteria. To our 
knowledge, abulia has never been formally assessed in HD. 
Anhedonia: Anhedonia is described as the ‘difficulty to anticipate 
or experience pleasure [49]. Generally, anhedonia is not considered 
a syndrome in its own right but rather a symptom of different 
psychopathologies such as depression and schizophrenia [39]. It may 
also be part of the apathy syndrome following the criteria of Marin and 
subsequent revisions. According to the DSM-V, a patient experiencing 
anhedonia reports less pleasure from daily activities (the focus here is on the 
subjective emotional experience of the patient) or loss of interest in those 
activities (slightly more focused on interpersonal behavioral aspects). The 
apparent overlap with apathy is striking, particularly considering the recent 
efforts in operationalizing both apathy and anhedonia within the context 
of disrupted reward processing systems and the role of dopaminergic 
frontostriatal circuits in both constructs.
In HD, anhedonia has been studied in the context of hedonic 
Authors Marin [29] Starkstein and Leentjens [28] International task force [38]
Temporal 
dimension None At least 4 weeks during most of the day At least 4 weeks during most of the time
Inclusion 
Criteria
State of primary motivational 
impairment.
(Marin’s conceptualization 
of apathy was done as 
a description and not as 
diagnostic criteria.)
A. Lack of motivation relative to the patient’s 
previous level of functioning or the standards of 
his or her age and culture as indicated either by 
subjective account or observation by others.
B. Presence for at least 4 weeks during most of the 
day, of at least 1 symptom belonging to each of the 
following 3 domains:
Diminished goal directed behaviour
1. Lack of effort or energy to perform everyday 
activities.
2. Dependency on prompts from others to structure 
everyday activities.
Diminished goal directed cognition
1. Lack of interest in learning new things, or in new 
experiences.
2. Lack of concern about one’s personal problems.
Diminished concomitants of goal directed behaviour
1. Unchanging or flat affect
2. Lack of emotional responsivity to positive or 
negative events.
C. The symptoms cause clinically significant distress 
or impairment in social, occupational or other 
important areas of functioning.
A. Loss of or diminished motivation in comparison to the patient’s 
previous level of functioning and which is not consistent with his 
age or culture. These changes in motivation may be reported by the 
patient himself or by the observations of others.
B. Presence of at least 1 symptom in at least 2 of the 3 following 
domains for a period of at least 4 weeks and present most of the 
time
B1. Loss of or diminished, goal-directed behaviour as evidenced by 
at least 1 of the following: 
- Loss of self-initiated behaviour (e.g. starting conversation, 
doing basic tasks of day-to-day living, seeking social activities, 
communicating choices)
- Loss of environment-stimulated behaviour (e.g. responding to 
conversation, participating in social activities)
B2. Loss of or diminished, goal-directed cognitive activity as 
evidenced by at least 1 of the following:
- Loss of spontaneous ideas and curiosity for routine and new events 
(i.e., challenging tasks, recent news, social opportunities, personal/
family and social affairs).
- Loss of environment-stimulated ideas and curiosity for routine 
and new events (i.e., in the persons residence, neighbourhood or 
community)
B3. Loss of or diminished, emotion as evidenced by at least 1 of the 
following:
- Loss of spontaneous emotion, observed or self-reported (e.g., 
subjective feeling of weak or absent emotions, or observation by 
others of a blunted affect)
- Loss of emotional responsiveness to positive or negative stimuli 
or events (e.g., observer-reports of unchanging affect, or of little 
emotional reaction to exciting events, personal loss, serious illness, 
emotional-laden news)
C. These symptoms (A-B) cause clinically significant impairment 
in personal, social, occupational or other important areas of 
functioning.
Exclusion 
criteria
‘Lack of motivation is not 
attributable to a diminished 
level of consciousness, an 
intellectual deficit or emotional 
distresses’.
D. The symptoms are not due to diminished level of 
consciousness or the direct physiological effects of 
a substance.
D. The symptoms (A-B) are not exclusively explained or due 
to physical disabilities (e.g. blindness and loss of hearing), to 
motor disabilities, to diminished level of consciousness or to the 
direct physiological effects of a substance (e.g. drug of abuse, a 
medication).
Table 2: Summary of apathy main conceptualizations, from Marin’s first description to the latest diagnostic criteria formulation.
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olfaction. In a very small study, 15 patients at various stages of HD 
had lower hedonic ratings compared to controls as well as a narrower 
hedonic rating range [50]. Currently there is an ongoing study that 
aims to assess hedonic olfaction in HD has the potential to differentiate 
anhedonia and apathy from depression [51]. This study has been 
designed to compare the hedonic perception of odours between patients 
with HD and matched controls and correlate hedonic olfaction with 
questionnaire-based assessments of depression, apathy and anhedonia. 
A further discussion awaits publication of the results from this on-
going study.
Alexithymia: Alexithymia is defined as a dysfunction in the 
cognitive processing of emotion that results in the diminished 
subjective feeling of these states [52]. Like apathy, it has been described 
as a symptom in several psychiatric disorders such as depression, post-
traumatic stress disorder (PTSD) and progressive supranuclear palsy 
among others [53] as well as a personality trait [52]. The two constructs 
(namely alexithymia and apathy) also share a common neurobiological 
basis as it is believed that alexithymia may also be a consequence of 
dopamine depletion and alterations in front temporal brain structures 
and the anterior cingulate cortex [37,53,54]. 
In a study of 353 patients with PTSD, apathy was found to be 
highly correlated with alexithymia, depression and emotional blunting 
but all were identified as distinct conditions that could be assessed 
independently. Interestingly, the only study analyzing the relationship 
between apathy and alexithymia in HD, found no correlation between 
the two. However, the study sample consisted of only 13 patients 
with HD and so no robust conclusions can be drawn from this. Thus, 
while the constructs of apathy and alexithymia appear to overlap 
and are frequently co-morbid [53], their relationship to one another, 
particularly in HD, is still unknown.
Assessment of Apathy in Huntington’s Disease
Apathy is usually assessed using psychometric tools. These are used 
to provide objective measures of symptom severity, their change over 
time and to evaluate the effectiveness of treatments and so are of critical 
importance for the clinic and research settings. However, to date, no 
such tool has been properly validated for use in patients with HD. 
Nevertheless, several rating scales are currently available and the most 
commonly used in HD are reviewed below.
Clinician lead, semi-structured interviews
The unified Huntington’s disease rating scale (UHDRS)-
behavioural scale [55]: The UHDRS is a clinical rating scale used to rate 
four domains in HD: motor function, cognitive function, behavioural 
abnormalities and functional capacity. The behavioural assessment 
is composed of 10 items that refer to symptoms in the last 6 months, 
scored between 0 and 4, in progressive severity. Only one item pertains 
to apathy (‘inability to enjoy anything’) and is included in the general 
category of Mood. 
The problem behaviour assessment for Huntington’s disease 
(PBA-HD) [56]: A semi-structured clinical interview modelled after 
the behavioural section of the UHDRS. The scale comprises 40 items 
covering an extensive range of neuropsychiatric symptoms including 
apathy. The items pertain to the last 4 weeks and are scored separately 
for frequency and severity between 0 and 5, in progressive order. In the 
study of Craudfurd et al. [56] apathy was considered present if a severity 
score of 2 or higher was obtained. Naarding et al. [17], in a sample of 
patients with HD, found apathy scores on the PBA to be significantly 
correlated with total Apathy Evaluation Scale scores (AES, described in 
section 3.2.1.). This factor structure was also corroborated in a shorter 
version of the PBA, the PBA-s [57].
Neuropsychiatric Inventory (NPI) [58]: an informant-based 
interview originally developed to assess neuropsychiatric symptoms in 
dementia. It entails one item dedicated to apathy in the last 4 weeks 
(‘Does he/she seem less interested in his/her usual activities or in the 
activities of others?’). If the answer is affirmative, informants are asked 
to assess this behaviour in terms of severity and frequency. Several 
studies have used the NPI to assess apathy symptoms in HD [16,59]. 
Structured Clinical Interview for Apathy [60]: Designed to screen 
for symptoms of apathy as operationalized by Starkstein and colleagues, 
in patients with Alzheimer’s disease. This interview includes questions 
referring to lack of motivation relative to the individual’s previous 
level of functioning, lack of effort to perform every day activities, lack 
of interest in learning new things or in new experiences, lack of self-
concern, flat affect and lack of emotional response. Additional follow 
up questions are used to rate the severity of symptoms, the approximate 
date of onset, the pattern of progression and discrepancies in the 
information provided by patient and caregiver. Apathy is diagnosed if 
a patient scores 3 on criterion A and on at least three B criteria and 
a score of 1 on criteria C and D. This interview, along with AES and 
UHDRS, was used as an outcome measure in the first drug trial for 
apathy in HD [61].
All these instruments are clinician lead, semi-structured interviews 
with the patient and/or their companion. Only the Structured Clinical 
Interview for Apathy does not look at apathy as part of a composite 
of many other behavioural features of HD. These assessments are 
time consuming to administer (approximately 30 min each) and their 
accuracy is highly dependent upon the skill and training of the clinician 
administering it which limits the utility of the scales in many settings. 
Additionally, while these interviews provide data about apathy at 
the global level they are insensitive to the finer details. For example, 
patients whose apathy is mild in severity but occurs frequently may 
have the same total domain score as a patient with occasionally has 
severe episodes of apathy. Thus, using such tools can make it difficult 
to detect subtle changes that may occur as a result of any therapeutic 
intervention. Therefore, in such circumstances it may be relevant to 
consider severity and frequency independently.
Rating scales
There is an extensive list of psychometric scales published to assess 
apathy [46,62,63], however, for the purpose of this review we have 
focused on those which have been published using HD patients. 
Apathy evaluation scale (AES)30 is based upon Marin’s 
conceptualization of apathy. There are three versions of the AES: 
Clinician (AES-C), informant (AES-I) and self-rated (AES-S) versions. 
Administration time is approximately 5 min. All versions include the 
same core 18 items presented in a 4 point likert scale, with a higher 
score indicating a greater severity of apathy. Several cut-off score have 
been proposed, according to different studies and clinical samples 
[30,64,65]. In samples of patients with HD, cut-offs of 4017 and 4165 
have been used to differentiate patients with clinically significant apathy 
in patient rated AES. For the companion rated AES, a cut-off of 39 has 
been used to be indicative of apathy in HD [65].
The apathy scale (AS) [66]: Is a short modified version of the 
Apathy Evaluation scale. It comprises of 14 items distributed in a 4 
point likert scale that is administered by a clinician. 
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The AES has proven to have satisfactory psychometric properties in 
healthy controls [30] and in several clinical samples [30,67,68]. However, 
no proper validation of the AES has been performed in a population 
of patients with HD and appropriate cut-offs are still lacking. Several 
threshold values have been proposed for clinically significant apathy 
(ranging from 30 to 41.5) and there is no clear consensus on which 
one to use making cross study comparisons difficult [69]. Furthermore, 
the widespread use of the AES across different clinical populations, 
whilst making it useful for cross-cohort comparisons, can lead to 
the assumption that different etiologies result in the same apathetic 
phenotype which is a preconception that has not been empirically 
verified. Further research is needed to ascertain whether the AES can 
detect differences in apathy profile between different neurodegenerative 
disorders.
Irritability-apathy scale [70]: It is an informant questionnaire 
developed for use in patients with Alzheimer’s Disease (AD) and 
HD. The companion of the patient is asked to rate the presences of 5 
symptoms of apathy since the onset of their disease on a 5 item likert 
scale. Apathy is considered as clinically significant if a patient obtains 
a score of ≥ 4 on items 1 and 3 and a score of ≥ 3 on items 2, 4 and 5. 
Because the Irritability-Apathy Scale asks the companion to compare 
symptoms before and after a diagnosis, it is not suitable for studies with 
premanifest HD patients. Apart from the validation study, to the best of 
our knowledge, this scale has not been used in any HD studies.
Frontal system behavioral scale (FrSBE) [62]: FrSBE is a 46-
item self-report symptom inventory designed to assess behavioural 
disturbances associated with damage to the frontal-subcortical brain 
circuits. Symptoms are scored on a 5 item likert scale for frequency and 
distress of a given symptom before and after a specific illness or injury. 
Because the FrSBE refers to symptoms before and after the diagnosis, it 
is not suitable for studies with premanifest HD patients. Three subscales 
can be derived: Apathy, Disinhibition and Executive Dysfunction. 
The apathy subscale has 14 items referring to difficulties in initiation, 
spontaneity, loss of interest and decreased concern about self-care. This 
scale is also be known in the HD literature as frontal lobe personality 
scale (FLOPS) [21].
The Huntington’s disease-behavioural questionnaire (HD-BQ) 
[71]: It is a quick screening tool for common behavioural changes in 
HD. It consists of 30 items that cover apathy, depression, irritability, 
anxiety and disinhibition. Items are rated on a 3-point likert scale with 
higher scores indicating more behavioural changes. A maximum score 
of 90 is possible and the assessment takes about 5 min to complete. The 
full paper on this instrument is yet to be published, therefore details on 
the specific assessment of apathy are not available. To our knowledge 
this scale has not yet been used outside of the validation studies.
None of the psychometric instruments described above have 
been validated against external criteria due to the lack of established 
diagnostic standards [46]. Furthermore, they are all based on slightly 
different definitions of apathy, so the scores obtained may not be 
directly comparable [72]. 
Furthermore, it is important to remember that when evaluating 
apathy in HD using subjective psychometric tools, it is crucial to 
consider potential confounding factors such as comorbid depression 
[17], adverse effects of concomitant medication [22] and lack of insight 
[61]. While there is a tendency to believe that patients with apathy rate 
their symptoms of apathy as significantly less severe than the caregivers 
or clinicians, the literature seems to be conflicting. Mason and Barker65 
found a strong correlation between self-rated and companion-rated 
AES scores. However, the degree of agreement varied across disease 
stage, so despite there being a high degree of agreement in early disease, 
when cognitive performance is preserved, patients tend to rate their 
levels of apathy higher than their companions in later disease stages. 
Additionally, the reliance on a companion report can be problematic 
when designing a clinical trial, as it restricts the cohort of eligible 
patients to those who have a reliable companion willing to accompany 
them for study visits. This also has the potential to create an additional 
potential recruitment bias, as patients with a good support network 
tend to fare better psychiatrically than those without [65].
Novel assessment techniques
Despite psychometric scales being the only currently available 
tools to assess apathy in HD, their use poses several limitations. 
Firstly, interviews are time consuming and require extensive training 
to be completed accurately which puts practical limitations on the 
number of patients who can be assessed using this method. Secondly, 
questionnaires are of limited use in the later stages of the disease due 
to increasing cognitive impairment and decreasing insight which 
make the responses unreliable. Furthermore, all self-report measures 
are subject to cultural and personality biases which may confound 
the data. Finally, reliance upon these current assessment tools limits 
the potential to translate between patients and non-human models of 
apathy which can provide a more mechanistic understanding of the 
neurobiological mechanisms that underlie this condition. Thus, more 
objective measures of apathy are needed.
Psychophysiological measures: David et al. [73] assessed daytime 
motor activity with wrist actigraphs in patients with AD as a surrogate 
marker of apathy. They found that those patients who had symptoms 
of apathy (as measured by the NPI) had significantly lower daytime 
mean motor activity compared with patients without apathy, while 
there was no difference in mean night-time motor activity between 
the two groups. Furthermore, in a sample of patients with traumatic 
brain injury, Andersson et al. [74] found that apathy (as measured by 
the AES) was significantly correlated with heart rate reactivity but not 
with electrodermal reactivity. However, to our knowledge, neither skin 
conductance nor heart rate reactivity have been used in the context of 
apathy research in HD. Furthermore, whilst these measures provide 
interesting support to the subjective assessments, they have limitations 
especially in HD where motor and autonomic abnormalities form part 
of the disease process.
Cognitive measures: Recently, there has been a move towards 
using effort-based and reward-based decision-making tasks [42] as an 
objective measure of apathy. In the HD literature, McLauchlan et al. [75] 
designed a battery of tasks that measured reward, sensitivity to negative 
stimuli and decision-making to encompass the different dimensions 
of apathy and looked at the association between performance on these 
tasks and scores on the PBA and AES in 53 mutation carrier individuals. 
They found that performance on both scales correlated with impaired 
sensitivity to negative stimuli and deficits in decision making but not 
to measures of effort, reward or learning. It was concluded that apathy 
was a result of inertia due to an impaired ability to formulate and enact 
a plan to change current behaviour. At present their work is published 
as a conference poster and therefore a more complete discussion awaits 
the full publication of their data. 
Neurobiology of Apathy
Apathy is most commonly associated with lesions in and 
dysfunction of, the prefrontal cortex (PFC) and basal ganglia (BG) [37]. 
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However, the neurobiological substrates driving apathy in the context 
of HD are currently not well understood. This is further complicated 
by the realization that they may vary according to disease stage and the 
exact “type” of apathy being described. 
Neuroimaging changes
Classical neuropathological studies in HD have shown that 
the striatum is the major site of early pathology becoming evident 
in the premanifest stage, after which the pathology becomes more 
widespread [76]. Given that apathy also appears early in the disease 
and gets progressively worse, it seems logical to explore the relationship 
between striatal pathology and apathy in HD. In the only study to do 
this, Duff and colleagues reported that higher scores on both the patient 
and companion versions of the FrSBe apathy subscale correlated with 
smaller striatal volumes in 558 premanifest HD gene carrires [77]. 
It is well known that the early striatal degeneration in HD 
compromises the functional integrity of the cortico–basal ganglia 
networks [78,79]. In particular, it is the role of the so called “limbic 
loop” [80] that may be particularly relevant to the understanding 
of apathy in HD. The limbic loop involves the ventral striatum and 
receives projections from the cingulate, orbital and prefrontal cortices 
[81]. These regions are linked to emotional processing, mood and affect 
and overlap with the areas proposed by Levy & Dubois to be involved 
with apathy [37]. 
In support of this Martinez-Horta et al. [82] performed an 18-
FDG PET/CT scan in a sample of 11 premanifest HD patients in 
whom they had assessed apathy and depression severity. Apathy scores 
(measured by the short version of PBA) significantly correlated with 
hypometabolism in the dorsolateral PFC, right frontopolar PFC and 
left posterior insula, while depressive scores were associated with 
hypometabolism in parietal-temporal regions.
Furthermore, Delmaire et al. [78] observed white matter changes 
in the gyrus rectus bilaterally of 27 patients with HD which correlated 
negatively with apathy scores, as measured by the Problem Behaviours 
Assessment (PBA). They did not, however, find a correlation between 
abnormalities in the ventral striatum and apathy scores. In contrast, 
Gregory et al. [83] investigated the relationship between apathy and 
white matter microstructure in a larger group of 38 premanifest and 43 
manifest patients and found no relationship between PBA apathy scores 
and fractional anisotropy (FA), even when the effect of medications was 
controlled for. It is likely that these contradictory results come from 
methodological differences, including different measures of apathy. 
For example, Gregory had a larger sample size but used a group of 
premanifest patients as their control group, whereas Delmaire used a 
healthy control group and a more advanced group of manifest patients. 
Also, while both studies used the PBA with mean scores that did not 
differ between the clinical groups, the DTI technique was slightly 
different and Gregory collated imaging data from multiple centres. 
Gregory et al. [83] also advanced other plausible reasons for the lack 
of association between apathy and white matter integrity, namely, an 
inherent bias of HD patients with more severe apathy are less likely to 
participate and the participants who do participate do not have marked 
white matter microstructural changes. While this bias is an important 
confounding effect of all apathy studies, the participants in Gregory’s 
study had a mean apathy score that was well above the PBA clinical cut-
off of 2 and is therefore unlikely to be the sole factor for the absence of 
an association. The authors propose that apathy in HD is related not to 
white matter microstructural changes but instead to that of grey matter. 
While this association has been found in studies with PD patients [84] 
we are not aware of any published data on the relationship between 
whole brain grey matter density and apathy in HD. Future research on 
grey and white matter density and apathy severity could prove to be 
useful to delineate potential intervention targets in treating this aspect 
of HD.
Neurotransmitters
Surprisingly, to the best of our knowledge, no study has focused on 
the role of dopamine (DA), serotonin or other neurotransmitters on 
apathy severity in HD. The lack of treatments for apathy accentuates the 
little knowledge we have of its neurobiological basis. Yet, untangling 
this aspect of the condition would allow for the development of effective 
treatments. Consequently, the evidence reported here has mostly been 
extrapolated from other neurodegenerative diseases or derived from 
the current knowledge of neurotransmitter dysfunction in HD.
Dopamine: Dopaminergic abnormalities in the CNS have been 
widely described in HD (for a comprehensive review see Schwab et 
al. [85]). Moreover, the dopaminergic system has been implicated in 
different component processes of reward, mainly mediating anticipatory 
phases, reinforcement processes and hedonic response [86,87]. Hence, 
dopamine could be a key neurotransmitter in the development and/or 
management of apathy in HD.
Although currently non-existent, studies regarding the effect of 
dopaminergic medication on apathy in HD could provide important 
insight into the role of this neurotransmitter. PD, AD and lesion studies 
suggest that dopaminergic receptor agonists improve apathy symptoms, 
hypothesizing that this is a result of improved dopaminergic input to 
the basal ganglia and frontal lobes [88,89]. The complete withdrawal 
of dopaminergic medication following deep brain stimulation for PD 
has also been shown to markedly increase apathy scores resulting in the 
need to restart these medications in some cases [90,91]. 
In HD patients, Mason and Barker [65] examined the impact of 
dopamine blocking drugs (e.g., sulpiride, amisulpiride, olanzapine, 
tetrabenazine and haloperidol) on apathy severity, as measured by the 
Apathy Evaluation scale. They found no difference in apathy scores, as 
assessed by the patient or their companion, between HD patients on 
antidopaminergic medication and HD patients who were not. Martinez-
Horta et al. [15] in a large cohort of premanifest individuals and 
patients with early HD, did (in contrast) find a significant correlation 
between apathy scores and use of antidepressants and neuroleptics. 
However, these are observational studies and therefore cannot provide 
any information about causality. 
Although it is currently unclear whether these drugs are 
contributing to the changes in affect seen in patients in HD, clinicians 
are recommended to exclude iatrogenic causes of apathy when 
managing patients and to consider a reduction of neuroleptics in HD 
apathetic patients if motor symptoms allow it [22,92].
It is also important to acknowledge that neurotransmitters do not 
act in isolation, for example, serotonergic innervation of the anterior 
striatum may exert a facilitatory influence on DA release [93].
Serotonin: The serotoninergic system has of late been implicated 
in the mediation of reward and in motivation but the literature is 
currently somewhat inconsistent. Both a reduction in activation elicited 
by rewarding stimuli in the ventral striatum and orbitofrontal cortex 
following administration of Selective Serotonin Reuptake Inhibitors 
(SSRIs) [94] and an increase in activation of reward on brain structures 
such as the ventral tegmental area have been shown [95]. Furthermore, 
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some studies have documented improvements in apathy scores after 
administration of SSRIs [44,96]. Still, this evidence consists of case 
reports and it is not clear whether an adequate differential diagnosis 
between depression and apathy was achieved in these cases. Therefore, 
there it is likely that the serotoninergic system is involved in apathy but 
the exact nature of its role is currently unclear. 
In the HD literature, little had been done to solve the relationship 
between apathy and the serotonergic system. While no study has 
directly looked at this, some reports exist that speak to it. Mason and 
Barker [65] examined the impact of SSRIs on apathy and found that 
apathy scores did not differ significantly as a function of antidepressant 
use, when depression symptoms were controlled for. On the other hand, 
Naarding et al. [17] found a positive correlation between antidepressant 
use and apathy score on the PBA and in a previously described study, 
Martinez-Horta et al. [15] also showed a significant correlation between 
apathy scores and use of antidepressants. However, neither study looked 
specifically at SSRI’s. 
Other neurotransmitters: There is evidence favouring the 
participation of several other neurotransmitters in the pathogenesis 
of apathy, including the GABAergic, cholinergic and glutamatergic 
systems [46]. However, while none of these neurotransmitters have 
been studied in the context of apathy in HD, it does highlight that the 
successful treatment of apathy may involve drugs affecting more than 
one neurotransmitter system.
Future Research Directions
Throughout the course of this review the poverty of research 
into apathy in HD has become apparent (Table 3). Currently it is not 
possible to present an empirically validated holistic synopsis of what 
apathy looks like in HD, nor how it impacts patients or what causes 
it. This is partially due to the methodological differences in the few 
existing studies, specifically in the classification of the stages of disease 
as well as the assessment tools they used to measure apathy, but also due 
to the overall scarcity of literature on the subject. Given the importance 
of apathy to both patients with HD and their families who are trying to 
care for them, this needs to be rectified.
Simple changes, such as adopting a consistent approach to defining 
and measuring apathy could have a meaningful and important impact 
to better understand this aspect of HD. For example, by using the 
consensus criteria identified by the International Task Force [38] as 
a framework for all future research, it would be possible to compare 
across studies in a meaningful way. Also, given the increased scope of 
this definition, it would allow for a true appreciation of the full breadth 
of apathetic symptoms experienced by patients. 
Conclusion
Given this, a primary focus of future work should be to clearly 
define the specific characteristics of apathy in HD and how it evolves 
across the disease course. Attention should be paid as to whether this 
profile of symptoms is universal across all patients or if subgroups can 
be identified that reflect people who either have a more aggressive 
or more benign phenotype. Doing so will allow for a more focused 
approach to identifying the underlying etiology of apathy in HD which 
in turn could lead to more effective treatments, for this most disabling 
of clinical features. 
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